Immune checkpoint inhibitor induced large vessel vasculitis

Daisy Henderson; Gelareh Eslamian; Daniel Poon; Simon Crabb; Robert Jones; Peter Sankey; Bihani Kularatne; Mark Linch; Debra Josephs

doi:10.1136/bcr-2019-233496

Immune checkpoint inhibitor induced large vessel vasculitis

BMJ Case Rep. 2020 May 18;13(5):e233496. doi: 10.1136/bcr-2019-233496.

Authors

Daisy Henderson¹, Gelareh Eslamian², Daniel Poon³, Simon Crabb⁴, Robert Jones⁵, Peter Sankey⁶, Bihani Kularatne⁷, Mark Linch⁸, Debra Josephs²

Affiliations

¹ Department of Palliative Care, Royal Free London NHS Foundation Trust, London, UK [email protected].
² Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
³ Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁴ Cancer Sciences Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
⁵ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁶ Department of Clinical Oncology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
⁷ Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
⁸ Department of Oncology, University College London Cancer Institute, London, UK.

Abstract

This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).

Keywords: cancer intervention; immunology; prostate cancer; unwanted effects / adverse reactions; vasculitis.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects*
Ipilimumab / adverse effects
Male
Nivolumab / adverse effects
Vasculitis / chemically induced*
Vasculitis / diagnosis*
Vasculitis / drug therapy

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab